Nicotine Reinforcement and Smoking-Cue Reactivity: Association With Genetic Polymorphisms

NCT ID: NCT02921282

Last Updated: 2024-03-08

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

26 participants

Study Classification

OBSERVATIONAL

Study Start Date

2016-08-31

Study Completion Date

2019-11-29

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

In this study, potential associations between several genetic polymorphisms and nicotine dependence will be examined. The relative reinforcing efficacy of cigarettes using the forced-choice procedure will be assessed. In addition, reactivity to smoking cues using a reliable procedure will be conducted.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

It is known that cannabinoid and dopamine receptors can be important modulators of response to nicotine and its associated cues. In this study participants will be genotyped to determine whether there is a relationship between CB1 or D3 genes and the reinforcing properties of nicotine or the subjective effects of nicotine-associated cues. In one session, participants will chose between two different cigarettes, each with different properties. In another session, physiological responses and craving will be measured when presented with cues that remind participants of nicotine. At some point during the study, blood will be collected for genotyping and this will processed to study whether CB1 or D3 genotype influences these responses to nicotine or cues.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Cigarette Smoking Behavior

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

OTHER

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Genotype dopamine

Genotyping will be conducted at the conclusion of the study

Genotype dopamine

Intervention Type GENETIC

Laboratory investigations of nicotine reinforcement

Genotype cannabinoids

Intervention Type GENETIC

Laboratory investigations of nicotine reinforcement

Genotype cannabinoids

Genotyping will be conducted at the conclusion of the study

Genotype dopamine

Intervention Type GENETIC

Laboratory investigations of nicotine reinforcement

Genotype cannabinoids

Intervention Type GENETIC

Laboratory investigations of nicotine reinforcement

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Genotype dopamine

Laboratory investigations of nicotine reinforcement

Intervention Type GENETIC

Genotype cannabinoids

Laboratory investigations of nicotine reinforcement

Intervention Type GENETIC

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. 19-64 year old males and females
2. smoking at least 10 cigarettes per day for at least 1 year
3. positive urinary cotinine
4. medically and psychologically healthy as determined by screening criteria

Exclusion Criteria

1. definite plan to reduce or quit tobacco use during the course of the study
2. treatment for tobacco dependence in the past 3 months
3. use of nicotine replacement products, bupropion, or varenicline in the past 3 months
4. consumption of more than 15 alcoholic drinks per week during the past month
5. use of any illicit drug more than twice per week during the past month
6. current use of any medication that would interfere with the protocol in the opinion of PI
7. under the influence of a drug or alcohol at any session
8. pregnant, nursing, or become pregnant during the study
Minimum Eligible Age

19 Years

Maximum Eligible Age

64 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Centre for Addiction and Mental Health

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Bernard Le Foll

Scientist

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Bernard Le Foll, MD PhD

Role: PRINCIPAL_INVESTIGATOR

CAMH

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Centre for Addiction and Mental Health

Toronto, Ontario, Canada

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Canada

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

134-2015

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Pharmacogenetics, Emotional Reactivity and Smoking
NCT00507728 COMPLETED PHASE2/PHASE3
Effects of Nicotine in Tobacco Smokers
NCT03651869 COMPLETED PHASE1